KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Leases (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Leases for 13 consecutive years, with $194.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases rose 1.97% year-over-year to $194.9 million, compared with a TTM value of $194.9 million through Dec 2025, up 1.97%, and an annual FY2025 reading of $194.9 million, up 1.97% over the prior year.
  • Leases was $194.9 million for Q4 2025 at Alnylam Pharmaceuticals, up from $191.4 million in the prior quarter.
  • Across five years, Leases topped out at $238.1 million in Q2 2021 and bottomed at $191.1 million in Q4 2024.
  • Average Leases over 5 years is $210.7 million, with a median of $206.1 million recorded in 2023.
  • The sharpest move saw Leases rose 7.2% in 2021, then dropped 9.11% in 2024.
  • Year by year, Leases stood at $231.7 million in 2021, then fell by 7.14% to $215.1 million in 2022, then dropped by 7.16% to $199.7 million in 2023, then decreased by 4.3% to $191.1 million in 2024, then grew by 1.97% to $194.9 million in 2025.
  • Business Quant data shows Leases for ALNY at $194.9 million in Q4 2025, $191.4 million in Q3 2025, and $192.4 million in Q2 2025.